Skip to main content
main-content

Zeitschrift

Cancer Immunology, Immunotherapy

Cancer Immunology, Immunotherapy OnlineFirst articles

17.11.2017 | Original Article

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients

The cancer immune escape is one of the most important features of cancer development, as reflected in the hallmarks of cancer by Hanahan and Weinberg [ 1 ]. Over decades, the aim of multiple studies was to further understand immune escape …

15.11.2017 | Focussed Research Review

Cancer vaccine strategies: translation from mice to human clinical trials

We translated two cancer vaccine strategies from mice into human clinical trials. (1) In preclinical studies on TARP, an antigen expressed in most prostate cancers, we mapped epitopes presented by HLA-A*0201, modified them to increase affinity and …

10.11.2017 | Original Article

Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor

Chimeric antigen receptor-modulated T lymphocytes (CAR-T) have emerged as a powerful tool for arousing anticancer immunity. Endogenous ligands for tumor antigen may outperform single-chain variable fragments to serve as a component of CARs with …

09.11.2017 | Original Article

Prophylactic DNA vaccine targeting Foxp3+ regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model

Regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC) are the two important and interactive immunosuppressive components of the tumor microenvironment that hamper anti-tumor immune responses. Therefore, targeting these two …

09.11.2017 | Original Article

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

Checkpoint inhibitor therapy has led to major treatment advances for several cancers including non-small cell lung cancer (NSCLC). Despite this, a significant percentage of patients do not respond or develop resistance. Potential mechanisms of …

Aktuelle Ausgaben

Über diese Zeitschrift

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.

In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:

  • “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.
  • “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.

CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT),and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).

CIMT: http://www.cimt.eu/home

CCIC: http://www.immunotherapycancer.ca/

JACI: http://www.jaci.jp/eng/index.html

NIBIT: http://www.nibit.org/index.php

SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK

CITIM: http://www.canceritim.org/

Weitere Informationen

Bestellen Sie jetzt e.Med Onkologie und erhalten Sie das Buch "Kachexie bei Tumorerkrankungen" als Prämie!

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.